Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 14/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866963 | 1.00 | FBP1 (0.47) | FBP1MEN1PSMD14KMT2AL3MBTL1 | |
| SCHEMBL1866964 | 1.00 | FBP1 (0.47) | FBP1MEN1PSMD14KMT2AL3MBTL1 | |
| SCHEMBL792983 | 0.79 | FBP1 (0.41) | FBP1VCPLMNAEGFRABL1 | |
| SCHEMBL11034872 | 0.79 | FBP1 (0.50) | FBP1VCPALDH1A1MAPTLMNA | |
| SCHEMBL792984 | 0.79 | FBP1 (0.41) | FBP1VCPLMNAEGFRABL1 | |
| SCHEMBL1363276 | 0.78 | FBP1 (0.47) | FBP1VCPALDH1A1MAPTNPSR1 | |
| SCHEMBL1363279 | 0.78 | FBP1 (0.47) | FBP1VCPALDH1A1MAPTNPSR1 | |
| SCHEMBL18874102 | 0.77 | DAO (0.39) | LMNA | |
| SCHEMBL14719039 | 0.71 | FBP1 (0.43) | FBP1MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL13692517 | 0.71 | FBP1 (0.43) | FBP1MEN1KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3317271-B1 | INHIBITORS OF EZH2 (ENHANCER OF ZESTE HOMOLOG 2) | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-20180162845-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| EP-3317271-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-05-09 | — | — | EP | disclosed |
| US-20170334891-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| EP-3212639-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-09-06 | — | — | EP | disclosed |
| WO-2017002064-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017002064-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016066697-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016066697-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334891-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | FBP1 448/4885MEN1 682/4885PSMD14 2091/4885 |
| US-20180162845-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | FBP1 448/4885MEN1 682/4885PSMD14 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.